Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma

Yunxia Liu, Shuichi Kimpara, Nguyet M. Hoang, Anusara Daenthanasanmak, Yangguang Li, Li Lu, Vu N. Ngo, Paul D. Bates, Longzhen Song, Xiaoyue Gao, Samantha Bebel, Madelyn Chen, Ruoyu Chen, Xiyu Zhang, Paul E. Selberg, Vaishalee P. Kenkre, Thomas A. Waldmann, Christian M. Capitini, Lixin Rui

Blood (2023) 142 (22): 1879–1894.

https://doi.org/10.1182/blood.2023020142

Published: 2023

Includes: Supplemental data

Journal Articles

Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma

Zhihui Song, Wenjun Wu, Wei Wei, Wenming Xiao, Michelle Lei, Kathy Q. Cai, Da Wei Huang, Subin Jeong, Jing-Ping Zhang, Hongbo Wang, Marshall E. Kadin, Thomas A. Waldmann, Louis M. Staudt, Masao Nakagawa, Yibin Yang

Blood (2023) 142 (15): 1297–1311.

https://doi.org/10.1182/blood.2022019166

Published: 2023

Includes: Supplemental data

Journal Articles

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Jonathan E. Brammer, Karen Ballen, Lubomir Sokol, Christiane Querfeld, Ryotaro Nakamura, Anjali Mishra, Eric M. McLaughlin, David Feith, Nazli Azimi, Thomas A. Waldmann, Yutaka Tagaya, Thomas Loughran

Blood (2023) 142 (15): 1271–1280.

https://doi.org/10.1182/blood.2022017643

Published: 2023

Includes: Supplemental data

Journal Articles

Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas

Masahiro Chiba, Joji Shimono, Takashi Ishio, Norio Takei, Kohei Kasahara, Reiki Ogasawara, Takahide Ara, Hideki Goto, Koh Izumiyama, Satoko Otsuguro, Liyanage P. Perera, Hiroo Hasegawa, Michiyuki Maeda, Satoshi Hashino, Katsumi Maenaka, Takanori Teshima, Thomas A. Waldmann, Yibin Yang, Masao Nakagawa

Blood (2022) 140 (18): 1951–1963.

https://doi.org/10.1182/blood.2022015646

Published: 2022

Includes: Supplemental data

Journal Articles

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

Blood (2022) 139 (10): 1541–1556.

https://doi.org/10.1182/blood.2021012734

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Albert, RN, Deborah Allen, RN, Thomas A. Waldmann, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142065

Published: 2020

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Kerry Rogers, Anjali Mishra, PhD, Thomas A. Waldmann, MD, Nazli Azimi, PhD PharmD, Paul Frohna, MD PhD PharmD, Anoshie Ratnayake, MD, Thomas P Loughran, Jr., MD, Karen Ballen, MD

Blood (2019) 134 (Supplement_1): 2835.

https://doi.org/10.1182/blood-2019-129291

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

Daniel A. Rauch, Kevin C. Conlon, Murali Janakiram, Jonathan E. Brammer, John C. Harding, B. Hilda Ye, Xingxing Zang, Xiaoxin Ren, Sydney Olson, Xiaogang Cheng, Milos D. Miljkovic, Hemalatha Sundaramoorthi, Ancy Joseph, Zachary L. Skidmore, Obi Griffith, Malachi Griffith, Thomas A. Waldmann, Lee Ratner

Blood (2019) 134 (17): 1406–1414.

https://doi.org/10.1182/blood.2019002038

Published: 2019

Includes: Supplemental data

Journal Articles

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Sarah Cooley, MD, Fiona He, MD BS, BA, Veronika Bachanova, MD PhD, Greg M Vercellotti, MD FACP, Todd E. DeFor, MS, Julie Curtsinger, Paul Alexander Robertson, MD, Kevin C Conlon, MD, Thomas A Waldmann, MD, David H. McKenna, MD, Bruce Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 2649.

https://doi.org/10.1182/blood.V130.Suppl_1.2649.2649

Published: 2017

Journal Articles

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Tracy Tiffany Wang, BS, Jun Yang, MD, Yong Zhang, PhD, Meili Zhang, PhD, Kevin C Conlon, MD, Yutaka Tagaya, B.M., PhD, Thomas L Olson, PhD, David J Feith, PhD, Nazli Azimi, Pharm.D., PhD, Thomas A. Waldmann, MD, Thomas P Loughran, Jr., MD

Blood (2017) 130 (Supplement 1): 3585.

https://doi.org/10.1182/blood.V130.Suppl_1.3585.3585

Published: 2017

Journal Articles

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Sigrid Dubois, PhD, Milos D. Miljkovic, MD, Thomas Fleisher, Jennifer Hsu, RN, Thomas A Waldmann, MD, Kevin C Conlon, MD

Blood (2017) 130 (Supplement 1): 3840.

https://doi.org/10.1182/blood.V130.Suppl_1.3840.3840

Published: 2017

Journal Articles

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T-Cell Leukemia/Lymphoma

Blood (2017) 130 (Supplement 1): 731.

https://doi.org/10.1182/blood.V130.Suppl_1.731.731

Published: 2017

Journal Articles

Role of Recipient CD8 + T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells

Robin Williams, MD MS, Sarah Cooley, MD, Veronika Bachanova, MD, Thomas A Waldmann, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD, Michael R. Verneris, MD

Blood (2016) 128 (22): 503.

https://doi.org/10.1182/blood.V128.22.503.503

Published: 2016

Journal Articles

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

Jeffrey S. Miller, MD, Michael R. Verneris, MD, Julie Curtsinger, PhD, Todd E. DeFor, MS, David McKenna, MD, Thomas A Waldmann, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD, Sarah Cooley, MD

Blood (2015) 126 (23): 566.

https://doi.org/10.1182/blood.V126.23.566.566

Published: 2015

Journal Articles

A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation

Masao Nakagawa, MD PhD, Roland Schmitz, PhD, Wenming Xiao, Carolyn K Goldman, Weihong Xu, Yandan Yang, PhD, Thomas A Waldmann, MD, Louis M. Staudt, MD PhD

Blood (2014) 124 (21): 3566.

https://doi.org/10.1182/blood.V124.21.3566.3566

Published: 2014

Journal Articles

Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation

Marcia Bellon, Nga Ling Ko, Min-Jung Lee, Yuan Yao, Thomas A. Waldmann, Jane B. Trepel, Christophe Nicot

Blood (2013) 121 (25): 5045–5054.

https://doi.org/10.1182/blood-2012-07-439109

Published: 2013

Includes: Supplemental data

Journal Articles

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Jing Chen, Cynthia A. Pise-Masison, Joanna H. Shih, John C. Morris, John E. Janik, Kevin C. Conlon, Anne Keating, Thomas A. Waldmann

Blood (2013) 121 (11): 2029–2037.

https://doi.org/10.1182/blood-2012-05-427773

Published: 2013

Includes: Supplemental data

NARROW

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma

Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T-Cell Leukemia/Lymphoma

Role of Recipient CD8 + T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation

Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only